Lantern Pharma Inc. (LTRN): Price and Financial Metrics
GET POWR RATINGS... FREE!
LTRN Stock Price Chart Interactive Chart >
LTRN Price/Volume Stats
| Current price | $5.87 | 52-week high | $7.92 |
| Prev. close | $6.00 | 52-week low | $4.19 |
| Day low | $5.73 | Volume | 10,364 |
| Day high | $6.00 | Avg. volume | 44,344 |
| 50-day MA | $5.45 | Dividend yield | N/A |
| 200-day MA | $5.36 | Market Cap | 63.73M |
Lantern Pharma Inc. (LTRN) Company Bio
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-11, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Latest LTRN News From Around the Web
Below are the latest news stories about LANTERN PHARMA INC that investors may wish to consider to help them evaluate LTRN as an investment opportunity.
LTRN: LP-184 & LP-284 in the SpotlightBy John Vandermosten, CFA NASDAQ:LTRN READ THE FULL LTRN RESEARCH REPORT Recent Program Updates Since Lantern Pharma, Inc. (NASDAQ:LTRN) announced 3Q:22 results in early November, there have been a number of program updates for LP-184 and LP-284. In late November, Lantern announced positive data regarding the anti-tumor potency of LP-184 in glioblastoma (GBM) and a few weeks later highlighted |
Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023DALLAS, January 17, 2023--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced it has received guidance from the United States Food and Drug Administration (FDA) on Lantern’s clinical development plans for its LP-184 program. LP-184 has shown nanomolar potency across a ra |
Should Lantern Pharma Inc. (NASDAQ: LTRN) Investors Be Concerned?The trading price of Lantern Pharma Inc. (NASDAQ:LTRN) closed higher on Friday, January 13, closing at $5.48, 0.92% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $5.42 and $5.64. In examining the 52-week price action we see that the stock hit a 52-week … Should Lantern Pharma Inc. (NASDAQ: LTRN) Investors Be Concerned? Read More » |
FDA grants orphan drug designation to Lantern Pharma''s lymphoma treatment candidateLantern Pharma (LTRN) said the U.S. FDA had granted an orphan drug designation to its LP-284 candidate for the treatment of mantle cell lymphoma. Read more here. |
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell LymphomaDALLAS, January 05, 2023--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the U.S. Food and Drug Administration (FDA) has granted LP-284 Orphan Drug Designation (ODD) for the treatment of mantle cell lymphoma (MCL). MCL is a rare and aggressive form of B-cell no |
LTRN Price Returns
| 1-mo | 5.77% |
| 3-mo | 36.83% |
| 6-mo | -3.61% |
| 1-year | -13.42% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -2.81% |
| 2022 | -24.31% |
| 2021 | -58.55% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...